The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
KSR1 gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab.
Marta Schirripa
No relevant relationships to disclose
Fotios Loupakis
No relevant relationships to disclose
Chiara Cremolini
No relevant relationships to disclose
Dongyun Yang
No relevant relationships to disclose
Melissa Janae Labonte
No relevant relationships to disclose
Wu Zhang
No relevant relationships to disclose
Lisa Salvatore
No relevant relationships to disclose
Takeru Wakatsuki
No relevant relationships to disclose
Rita El-Khoueiry
No relevant relationships to disclose
Carlotta Antoniotti
No relevant relationships to disclose
Giuseppe Aprile
No relevant relationships to disclose
Martin Karl Herbert Maus
No relevant relationships to disclose
Sara Lucchesi
No relevant relationships to disclose
Giacomo Allegrini
No relevant relationships to disclose
Fernando De Vita
No relevant relationships to disclose
Hua Zhang
No relevant relationships to disclose
Georgios Giamas
No relevant relationships to disclose
Justin Stebbing
No relevant relationships to disclose
Alfredo Falcone
No relevant relationships to disclose
Heinz-Josef Lenz
Consultant or Advisory Role - Bristol-Myers Squibb; Genentech; Merck KGaA